Immunotherapy Is Changing Cancer Treatment Forever
Immunotherapy and related approaches like CAR‑T and mRNA cancer vaccines are giving some patients dramatic, sometimes life‑saving responses, yet they remain unreliable, especially against solid tumors, and can cause severe long‑term side effects. Commenters weigh the ethical and regulatory tension between speeding access to experimental treatments for terminal patients and protecting people from unsafe, ineffective, or exploitative care, noting how trial design, FDA incentives, and limited slots complicate the picture. Many share personal experiences with late‑stage cancers, describing how hard it is to find and qualify for clinical trials and how high costs and slow evidence generation limit the promise of these therapies today.
Regulation, “right to try,” and ethics
- Several participants with advanced cancers express anger that therapies take “just” five years to approval, arguing terminal patients should be allowed almost anything that might help.
- Others counter that:
- Most promising treatments fail; rushing approvals without solid data could harm more people.
- FDA and companies have asymmetric PR risk: deaths from non‑approval are invisible; deaths after approval are highly visible, incentivizing caution.
- Compassionate use and “right to try” exist but depend on manufacturer and physician participation.
- There is debate over deregulation:
- One side emphasizes patient autonomy and the absurdity of telling dying people drugs are “too dangerous.”
- The other warns about corruption, “snake oil,” and doctors pushed or bribed into using unproven, expensive treatments, with concerns about who pays (e.g., Medicare).
Clinical trials, evidence quality, and controls
- Trials have strict eligibility; many patients become ineligible after multiple prior therapies or comorbidities.
- Participants note:
- Trials often lack overall survival endpoints, adequate sample sizes, or proper comparators.
- Control arms are still needed; you cannot reliably reuse old control data because patient populations change.
- It’s noted that few oncologists proactively steer patients into trials; motivated patients often must research and apply themselves.
Patient experiences with immunotherapy and CAR‑T
- Multiple accounts of:
- Immunotherapy or CAR‑T producing dramatic remissions or durable disease control.
- Severe side effects, including new autoimmune diseases (e.g., type 1 diabetes, thyroid/adrenal damage), pneumonitis, colitis, and profound immunosuppression with infection risk.
- Some patients accept high‑risk options; others decline CAR‑T to prioritize quality time with family.
- Quality of life trade‑offs are central; long‑term “financial toxicity” is also emphasized.
Cancer types, limits, and targets
- Solid tumors, especially ovarian and various rare subtypes, are repeatedly described as much harder to treat with immunotherapy than blood cancers.
- For ovarian cancer, participants mention ongoing trials and targeted therapies but say routine immunotherapy use may be decades away and very costly, especially when treatments must be individualized.
- Questions about mRNA cancer vaccines get the answer that work is ongoing with mixed but sometimes promising early results; they require suitable tumor targets.
Costs, scalability, and industry incentives
- Manufacture of personalized cell therapies is described as laborious, with eye‑watering prices (hundreds of thousands of dollars) and limited scalability.
- Some argue investors are cooling on immuno‑oncology; others in the field dispute this.
- There is ongoing tension noted between commercial incentives, trial design, and the needs of dying patients.